<DOC>
	<DOCNO>NCT00526591</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth . Giving everolimus surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This randomized phase II trial study side effect well everolimus work treat patient newly diagnose localized prostate cancer .</brief_summary>
	<brief_title>Everolimus Treating Patients With Newly Diagnosed Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine clinical effect everolimus , term pathologic response ( i.e. , histologic P0 , margin status , capsular penetration ) surgical outcome , patient newly diagnose localized prostate cancer treat two different dos everolimus prior radical prostatectomy . - To evaluate safety tolerability drug patient . Secondary - To determine effect drug prostate-specific antigen ( PSA ) level patient . - To determine effect drug level expression PTEN , Akt , phospho-mTOR ( i.e. , Se2448 ) , phospho-p70 S6 kinase ( i.e. , Thre389 ) , phospho-Smad3 ( i.e. , Ser433/435 ) , phospho-Smads 1/5 ( i.e. , Ser463/465 ) , AR , TUNEL patient . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I : Patients receive low-dose oral everolimus daily 8 week absence unacceptable toxicity . - Arm II : Patients receive high-dose oral everolimus daily 8 week absence unacceptable toxicity . Within 7 day last dose everolimus , patient undergo radical prostatectomy bilateral pelvic lymphadenectomy . Tumor biopsy specimen acquire prior treatment prostate tumor tissue acquire time radical prostatectomy evaluate biomarker correlative study . Tissue sample assess immunohistochemistry ( IHC ) tissue microarray analysis expression cellular molecular biomarkers ( i.e. , p-S6 , p-4E-BP1 , p-Akt ) correlate response . Prostatectomy specimens also assess pathologic analysis histopathologic response ( i.e. , pathologic stage , Gleason score , margin status , tumor size ) . After completion study therapy , patient follow 6 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm newly diagnose , localize adenocarcinoma prostate , meet follow criterion : Clinical stage T2a , T2b , T2c , T3 disease ( grade PSA ) Gleason score 7 ( 4+3 ) ≥ 8 ( stage PSA ) Serum PSA ≥ 10 ng/dL ( grade stage ) Any stage , PSA , Gleason score AND ≥ 35 % chance biochemical failure 5 year base Kattan 's nomogram Recommended radical prostatectomy Normal testosterone level No pure neuroendocrine small cell prostate cancer No metastatic disease CT scan , MRI , bone scan , Xray No clinical evidence CNS metastases PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status ( PS ) 01 Karnofsky PS 70100 % ANC ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 8 g/dL AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN PT/PTT normal ( anticoagulant ) No active unresolved infection No known HIV positivity Fertile patient must use effective contraception 6 month completion study therapy Exclusion criterion : Known hypersensitivity everolimus rapamycins ( e.g. , sirolimus temsirolimus ) excipients Gastrointestinal ( GI ) disease , condition , symptom may significantly impair GI function alter absorption everolimus , include follow : Ulcerative disease Uncontrolled nausea Vomiting Diarrhea Malabsorption syndrome Other active malignancy malignancy ≥ 30 % risk relapse completion therapy , except nonmelanoma skin cancer Uncontrolled concurrent illness include , limited , follow : Ongoing active infection ( e.g. , bacterial , viral fungal ) Severely impaired lung function Uncontrolled diabetes ( fast serum glucose &gt; 1.5 time ULN ) Liver disease ( e.g. , cirrhosis , chronic active hepatitis , chronic persistent hepatitis ) Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit study compliance Any underlying medical condition , principal investigator 's opinion , make administration everolimus hazardous OR obscure interpretation adverse event PRIOR CONCURRENT THERAPY : More 4 week since major surgery More 3 month since finasteride No prior concurrent radiotherapy prostate gland pelvis No prior hormone ( e.g. , luteinizing hormonereleasing hormone [ LHRH ] agonist , LHRH antagonists , antiandrogens [ e.g. , bicalutamide , flutamide , nilutamide ] ) and/or PCSPES ( PCx product ) estrogencontaining nutraceuticals No prior rapamycin mTOR inhibitor No prior small bowel resection may significantly impair GI function alter absorption everolimus No prior concurrent immunotherapy , chemotherapy , investigational therapy prostate cancer No concurrent investigational commercial agent No concurrent anticancer agents No concurrent , chronic treatment systemic steroid ( except inhale topical steroid ) another immunosuppressive agent No concurrent live vaccine No concurrent strong inhibitor inducer isoenzyme CYP3A administer systemic therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>